MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$208,237K
Net cash provided by
(used in) investing...
$94,860K
Effect of exchange rate
changes on cash, cash...
$23K
Canceled cashflow
$113,377K
Net change in cash,
cash equivalents and...
-$17,465K
Canceled cashflow
$94,883K
Deferred income taxes
$81,443K
Accounts payable and
other liabilities
$15,820K
Product revenue
allowances
$15,484K
Stock-based compensation
$9,474K
Intangible asset
amortization
$7,007K
Right-of-use asset
amortization
$3,807K
Other non-cash
adjustments, net
-$1,943K
Depreciation of property and
equipment
$1,103K
Purchases of marketable
securities
$112,379K
Purchases of property and
equipment
$998K
Net cash provided by
(used in) operating...
-$109,442K
Canceled cashflow
$136,081K
Net cash provided by
(used in) financing...
-$2,906K
Revenues
$216,105K
Other income
$12,521K
Net income (loss)
-$220,474K
Canceled cashflow
$228,626K
Prepaid expenses and
other assets
$12,067K
Accounts receivable
$7,463K
Inventory
$3,466K
Amortization of premiums and
accretion of discounts on...
$2,053K
Principal payments on
finance leases
$1,991K
Tax obligations
paid in connection...
$915K
Selling, general and
administrative
$237,951K
Research and development
$109,271K
Provision (benefit) for
income taxes
$81,827K
Cost of goods sold
excluding amortization
$13,044K
Intangible asset
amortization
$7,007K
Back
Back
Cash Flow
source: myfinsight.com
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)